The biotech stock rose after an analyst upgrade.
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and...
PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and...
– DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming...
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and...
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Cabaletta Bio, Inc. (“Cabaletta” or the “Company”)...
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta" or "the Company") (NASDAQ: CABA) and certain...
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cabaletta Bio, Inc. (NASDAQ: CABA): (i) pursuant and/or traceable to the offering documents issued in connection...
Shareholder rights law firm Robbins LLP is investigating Cabaletta Bio, Inc. (NASDAQ: CABA) and its officers and directors to determine if they breached their fiduciary duties and violated securities...